DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY STUDY IN ADVANCED MULTIPLE MYELOMA - AN OPEN-LABEL, DOSE ESCALATION FOLLOWED BY OPEN-LABEL EXTENSION IN A SINGLE-ARM PHASE I/II STUDY

被引：0
|
作者：
Lokhorst, H. [1 ]
Plesner, T. [2 ]
Gimsing, P. [3 ]
Nahi, H. [4 ]
Lisby, S. [5 ]
Richardson, P. [6 ]
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Vejie Hosp, Vejie, Denmark
[3] Copenhagen Univ Hosp, Copenhagen, Denmark
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Genmab A S, Copenhagen, Denmark
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S576
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [1] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [2] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [3] Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study
    Plesner, Torben
    Lokhorst, Henk
    Gimsing, Peter
    Nahi, Hareth
    Lisby, Steen
    Richardson, Paul G.
    BLOOD, 2012, 120 (21)
  • [4] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
    Schwartzberg, Lee
    Hermann, Robert
    Flinn, Ian
    Flora, Douglas
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Myrand, Scott P.
    Nguyen, Tuan S.
    Dreyling, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97
  • [5] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
    Harari, Sergio
    Elia, Davide
    Caminati, Antonella
    Geginat, Jens
    Luisi, Francesca
    Pelosi, Giuseppe
    Specchia, Claudia
    Torre, Olga
    Trevisan, Roberta
    Vasco, Chiara
    Zompatori, Maurizio
    Cassandro, Roberto
    LANCET RESPIRATORY MEDICINE, 2024, 12 (12): : 967 - 974
  • [6] Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients
    Tomita, Yoshihiko
    Tatsugami, Katsunori
    Nakaigawa, Noboru
    Osawa, Takahiro
    Oya, Mototsugu
    Kanayama, Hiroomi
    Kondoh, Chihiro Nakayama
    Sassa, Naoto
    Nishimura, Kazuo
    Nozawa, Masahiro
    Masumori, Naoya
    Miyoshi, Yasuhide
    Kuroda, Shingo
    Tanaka, Shingo
    Kimura, Akiko
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (11) : 952 - 959
  • [7] An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma
    Mei, Qian
    Chen, Meixia
    Lu, Xuechun
    Li, Xiang
    Duan, Feng
    Wang, Maoqiang
    Luo, Guangbin
    Han, Weidong
    ONCOTARGET, 2015, 6 (18) : 16698 - 16711
  • [8] A Prospective Open-label Single-Arm Phase II Study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients
    Varga, Z
    de Mulder, P
    Kruit, W
    Hegele, A
    Hofmann, R
    Lamers, C
    Warnaar, S
    Mala, C
    Ullrich, S
    Mulders, P
    FOLIA BIOLOGICA, 2003, 49 (02) : 74 - 77
  • [9] A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis
    Tempfer, Clemens B.
    Giger-Pabst, Urs
    Seebacher, Veronika
    Petersen, Miriam
    Dogan, Askin
    Rezniczek, Guenther A.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (01) : 23 - 30
  • [10] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
12345